Oberweis Asset Management’s Adaptive Biotechnologies ADPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$27M Buy
1,258,751
+451,800
+56% +$6.92M 0.56% 65
2026
Q1
$11.2M Buy
806,951
+62,451
+8% +$995K 0.33% 110
2025
Q4
$12.1M Buy
744,500
+18,000
+2% +$294K 0.44% 91
2025
Q3
$10.9M Buy
726,500
+137,100
+23% +$1.67M 0.42% 92
2025
Q2
$6.87M Buy
+589,400
New +$5.35M 0.3% 118

Other funds holding ADPT

Oberweis Asset Management's ADPT Position: Q2 2026 in Review

Oberweis Asset Management increased its Adaptive Biotechnologies (ADPT) stake by 56% in Q2 2026, buying an estimated $6.92M and bringing the position to 1,258,751 shares worth $27M. The position accounts for 0.56% of the portfolio, ranked #65.

Oberweis Asset Management first reported a position in ADPT in Q2 2025 and has held it in 5 quarters since. 301 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Oberweis Asset Management held 1,258,751 shares of Adaptive Biotechnologies worth $27M as of Q2 2026.
  • Oberweis Asset Management bought 451,800 Adaptive Biotechnologies shares in Q2 2026, an estimated $6.92M.
  • Adaptive Biotechnologies made up 0.56% of Oberweis Asset Management's portfolio in Q2 2026, its #65 holding.
  • Oberweis Asset Management first reported a position in Adaptive Biotechnologies in Q2 2025 and has held it in 5 quarters since.
  • 301 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Oberweis Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.